Patent directory · USPTO A61K / A61P
Patents matching “TEVA PHARMACEUTICAL INDUSTRIES, LTD.”
302 pharma patents match "TEVA PHARMACEUTICAL INDUSTRIES, LTD." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 302 pharmaceutical patents matching "TEVA PHARMACEUTICAL INDUSTRIES, LTD." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 9161935
Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
granted -
US 9155775
Process for manufacturing glatiramer acetate product
granted -
US 9107832
Risperidone microparticles formed by sublimation
granted -
US 9102620
Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
granted -
US 9090598
Nilotinib salts and crystalline forms thereof
granted -
US 9063153
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
granted -
US 9018170
Reduced volume formulation of glatiramer acetate and methods of administration
granted -
US 9012641
Crystalline forms of Prasugrel salts
granted -
US 8993519
Method of treatment for neutropenia using stable formulations of recombinant human albumin-human granulocyte colony stimulating factor
granted -
US 8975279
Amine salts of laquinimod
granted -
US 8946300
Use of rasagilline for the treatment of restless legs syndrome
granted -
US 8946167
Pharmaceutical compositions containing plasma protein
granted -
US 8937082
Nilotinib salts and crystalline forms thereof
granted -
US 8920373
Reduced volume formulation of glatiramer acetate and methods of administration
granted -
US 8889213
Processes for coating a carrier with microparticles
granted -
US 8889661
Treatment of lupus nephritis using laquinimod
granted -
US 8889627
Treatment of multiple sclerosis with combination of laquinimod and fingolimod
granted -
US 8865722
Wet formulations of aripiprazole
granted -
US 8815511
Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
granted -
US 8809310
Use of rasagiline for the treatment of multiple system atrophy
granted -
US 8809537
N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
granted -
US 8802854
Crystalline forms of Prasugrel salts
granted -
US 8759314
Methods for treating multiple sclerosis using antisense oligonucleotides
granted -
US 8759302
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
granted